Laboratory of Immune Regulation, World Premier International Immunology Frontier Research Center, Osaka University, Osaka, Japan.
Experimental Immunology, World Premier International Immunology Frontier Research Center, Osaka University, Osaka, Japan.
Cancer Immunol Res. 2021 Aug;9(8):862-876. doi: 10.1158/2326-6066.CIR-21-0014. Epub 2021 May 18.
The acquisition of mesenchymal traits leads to immune evasion in various cancers, but the underlying molecular mechanisms remain unclear. In this study, we found that the expression levels of AT-rich interaction domain-containing protein 5a (Arid5a), an RNA-binding protein, were substantially increased in mesenchymal tumor subtypes. The deletion of Arid5a in tumor cell lines enhanced antitumor immunity in immunocompetent mice, but not in immunodeficient mice, suggesting a role for Arid5a in immune evasion. Furthermore, an Arid5a-deficient tumor microenvironment was shown to have robust antitumor immunity, as manifested by suppressed infiltration of granulocytic myeloid-derived suppressor cells and regulatory T cells. In addition, infiltrated T cells were more cytotoxic and less exhausted. Mechanistically, Arid5a stabilized and mRNAs and augmented their expression, resulting in enhanced tryptophan catabolism and an immunosuppressive tumor microenvironment. Thus, our findings demonstrate the role of Arid5a beyond inflammatory diseases and suggest Arid5a as a promising target for the treatment of immunotolerant malignant tumors..
间质表型的获得导致各种癌症的免疫逃逸,但潜在的分子机制尚不清楚。在这项研究中,我们发现富含 AT 的相互作用域蛋白 5a(Arid5a)的表达水平在间质肿瘤亚型中显著增加。肿瘤细胞系中 Arid5a 的缺失增强了免疫功能正常的小鼠的抗肿瘤免疫,但在免疫缺陷小鼠中没有,这表明 Arid5a 在免疫逃逸中起作用。此外,Arid5a 缺陷型肿瘤微环境表现出强大的抗肿瘤免疫,表现为粒细胞髓源性抑制细胞和调节性 T 细胞浸润减少。此外,浸润的 T 细胞具有更强的细胞毒性和更少的耗竭。在机制上,Arid5a 稳定了 和 mRNA 并增加了它们的表达,导致色氨酸分解代谢增强和免疫抑制性肿瘤微环境。因此,我们的研究结果表明 Arid5a 在炎症性疾病之外的作用,并表明 Arid5a 是治疗免疫耐受恶性肿瘤的有前途的靶点。
Cancer Immunol Res. 2021-8
Cancer Immunol Res. 2021-8
Proc Natl Acad Sci U S A. 2016-10-11
Front Immunol. 2021
Proc Natl Acad Sci U S A. 2019-7-9
Nucleic Acids Res. 2017-3-17
Genes Dis. 2022-1-25
Cancers (Basel). 2024-12-6
World J Surg Oncol. 2023-8-22